MSU receives $1.1M grant to support mesothelioma caregivers

Fox Chase and Temple researchers receive $1.2M grant for animal studies on broccoli compound’s potential for mesothelioma prevention

Researchers at Fox Chase Cancer Center and Temple Health were recently awarded a three year, $1.2 million grant to study sulforaphane, a promising cancer preventive agent derived from broccoli and other cruciferous vegetables, for the prevention of malignant mesothelioma.

July 14, 2023

Vol.49 No.28

Clinical Roundup

Phase I MD Anderson study shows YAP/TEAD inhibitor VT3989 is well tolerated and shows antitumor activity in advanced mesothelioma and NF2-mutant cancers

The first-in-class YAP/TEAD inhibitor VT3989 was well tolerated with durable antitumor responses in patients with advanced malignant mesothelioma and other tumors with NF2 mutations, according to results of a phase I trial led by researchers at MD Anderson Cancer Center. The first-in-human study was presented today at the 2023 American Association for Cancer Research annual meeting.

April 21, 2023

Vol.49 No.16

In Brief

Andrea Wolf receives Irving J. Selikoff Lifetime Achievement Award from Asbestos Disease Awareness Organization

Andrea Wolf, director of the New York Mesothelioma Program at the Mount Sinai Health System, received the 2022 Irving J. Selikoff Lifetime Achievement Award from the Asbestos Disease Awareness Organization.

January 20, 2023

Vol.49 No.03

Obituary

Nicholas Vogelzang, an expert in GU cancers and mesothelioma, dies at 72

Nicholas Vogelzang, MD, 72, an internationally recognized oncologist who dedicated his professional life to researching and treating genitourinary cancers as well as mesothelioma, died on Sept. 20.

October 07, 2022

Vol.48 No.36

By Annette Westerberg, Everett E. Vokes and Walter M. Stadler

Drugs & Targets

FDA grants Fast Track designation to IK-930 in unresectable NF2-deficient mesothelioma

FDA granted Fast Track designation for IK-930, a novel TEAD inhibitor targeting the Hippo signaling pathway, in patients with unresectable NF2-deficient malignant pleural mesothelioma.

June 24, 2022

Vol.48 No.25